Fig. 8
PTH1-34 decrement of senescence-like astrocytes from 5XFAD mice. A RT-PCR analysis of senescence-related gene expression level in the cultured astrocytes with PTH1-34 or Veh treatment from WT and 5XFAD P3 female pups. GAPDH expression level was normalized to 1, n = 3 independent experiments. B SA-β-gal staining of cultured WT and 5XFAD astrocytes with PTH1-34 or Veh treatment. Scale bars as indicated in the panel. C Quantification of relative SA-β-gal + cell intensity in B (mean ± SD; n = 3 independent experiments). D RT-PCR analysis of senescence-related gene expression level in the hippocampus from 6 ~ MO WT or 5XFAD female mice with PTH1-34 or Veh treatment. GAPDH expression level was normalized to 1 (n = 3). E Western blot analysis of indicated protein expression in homogenates of hippocampus of 6 ~ MO WT and 5XFAD female mice with PTH1-34 or Veh treatment. F Quantification of relative protein level in E, n = 4 mice per group. All quantification data were presented as mean ± SD. *P < 0.05, **P < 0.01, one-way ANOVA with Tukey’s multiple-comparison test was used. G Summary of AD brain pathology and cognitive function differences in 5XFAD mice with Veh or PTH1-34 intermittent treatment. H Illustration of the working model